Biohaven Ltd. has announced that the FDA is extending the PDUFA date for the new drug application (NDA) of troriluzole, aimed at treating spinocerebellar ataxia $(SCA)$, by three months to allow for a comprehensive review of recent submissions from the company. This decision pushes the expected announcement to the fourth quarter of 2025. Troriluzole, which has already been granted Fast-Track, Orphan Drug Designation, and Priority Review by the FDA, would be the first and only FDA-approved treatment for the rare, genetic, and life-threatening neurodegenerative disease if approved. The FDA has not raised any new concerns and is planning an advisory committee meeting to discuss the application, though the date has not been set.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.